Zhejiang Yatai Pharmaceutical Co., Ltd.

XSEC:002370 Stock Report

Market Cap: CN¥2.0b

Zhejiang Yatai Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Zhejiang Yatai Pharmaceutical has been growing earnings at an average annual rate of 64.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 11.2% per year.

Key information

64.7%

Earnings growth rate

64.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-11.2%
Return on equity-2.7%
Net Margin-3.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Yatai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002370 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24426-1711616
30 Jun 24421-2611521
31 Mar 24410-1213122
31 Dec 23421-1213722
30 Sep 23441-5013829
30 Jun 23433-6114225
31 Mar 23429-10613127
01 Jan 23373-13313126
30 Sep 22331-21516222
30 Jun 22324-23616924
31 Mar 22304-23318925
01 Jan 22315-22820229
30 Sep 213723920330
30 Jun 214093824731
31 Mar 214452826435
31 Dec 205152728737
30 Sep 20344-2,03338863
30 Jun 20392-2,01437168
31 Mar 20490-2,00138067
31 Dec 19708-1,91936970
30 Sep 191,0764828954
30 Jun 191,22211727559
31 Mar 191,35719926557
31 Dec 181,31020826954
30 Sep 181,21721825744
30 Jun 181,25123225356
31 Mar 181,15622123350
31 Dec 171,08320221041
30 Sep 171,09419019630
30 Jun 179301631860
31 Mar 179031481740
31 Dec 168631251690
30 Sep 16758981470
30 Jun 16691881380
31 Mar 16575651320
31 Dec 15463551210
30 Sep 15397561060
30 Jun 15380501030
31 Mar 1537241940
31 Dec 1437641930
30 Sep 1437638910
30 Jun 1435936850
31 Mar 1433924900
31 Dec 133145890

Quality Earnings: 002370 is currently unprofitable.

Growing Profit Margin: 002370 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002370 is unprofitable, but has reduced losses over the past 5 years at a rate of 64.7% per year.

Accelerating Growth: Unable to compare 002370's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 002370 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 002370 has a negative Return on Equity (-2.65%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 16:09
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Yatai Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jie YaoEverbright Securities Co. Ltd.
Fenghua WangShenwan Hongyuan Securities